BERGEN, Norway, September 11, 2015 /PRNewswire/ --
BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that it has been awarded one of this year's Nordic Stars Awards at the Nordic Life Science Days 2015 conference held in Stockholm, Sweden on 9-10 September, 2015.
BerGenBio has been presented with this award in recognition of its market-leading innovation and entrepreneurial skills in the Nordic life science community.
On news of this award, Richard Godfrey, Chief Executive Officer of BerGenBio, commented:
"This is an exciting time for us at BerGenBio. We are making significant progress with BGB324, our first-in-class selective Axl inhibitor. We are proud to be honoured with this award as we continue to grow and establish ourselves as a leader in the development of innovative drugs for aggressive cancers."
Jonas Ekstrand, Director General SwedenBIO, organisers of the Nordic Stars Awards, said: "BerGenBio's deep biological understanding of epithelial-mesenchymal transition (EMT), immune evasion and metastasis makes them a worthy winner of this year's award. With its focus on ground‐breaking therapies and precision medicine, BerGenBio is a leading example and a Nordic Star."
About Nordic Life Science Days
Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities. Based on cutting-edge and advanced partnering and networking tools, Nordic Life Science Days showcases the best the Nordic region has to offer.
About BerGenBio AS
BerGenBio AS is a clinical stage biopharmaceutical company. The company is committed to developing innovative therapeutics that inhibit epithelial-mesenchymal transition (EMT), a widely recognised key pathway in immune evasion, acquired cancer drug-resistance and metastasis. The company is founded on proprietary platform technology, CellSelect™, which uses information from RNAi screening studies to identify and validate novel drug targets and biomarkers. BGB324 is the first compound in BerGenBio's pipeline to enter clinical trials in AML and NSCLC, and the company has additional compounds and drug targets at different stages of preclinical development. http://www.bergenbio.com